OPKO Pharmaceuticals, LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$14.2M
Doctors Paid
6,949
Transactions
55,304
2024 Total
$740,737
Payment Breakdown by Category
Research$12.4M (87.5%)
Food & Beverage$746,401 (5.2%)
Consulting$403,864 (2.8%)
Travel$12,316 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12.4M | 703 | 87.5% |
| Food and Beverage | $746,401 | 41,379 | 5.2% |
| Consulting Fee | $403,864 | 70 | 2.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $350,676 | 128 | 2.5% |
| Education | $211,941 | 12,921 | 1.5% |
| Honoraria | $39,923 | 35 | 0.3% |
| Space rental or facility fees (teaching hospital only) | $14,193 | 13 | 0.1% |
| Travel and Lodging | $12,316 | 53 | 0.1% |
| Gift | $9.90 | 2 | 0.0% |
Payments by Type
Research
$12.4M
703 transactions
General
$1.8M
54,601 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19 | $3.4M | 1 | 110 |
| Repeated-dose Safety, Efficacy, PK and PD of CTAP101, IR Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With SHPT, CKD 3-4 and VDI | $3.2M | 0 | 15 |
| Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI | $1.4M | 0 | 165 |
| A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTICENTER, 12 MONTHS, EFFICACY AND SAFETY STUDY OF WEEKLY MOD-4023 COMPARED TO DAILY GENOTROPIN THERAPY IN PRE-PUBERTAL CHILDREN WITH GROWTH HORMONE DEFICIENCY | $1.2M | 1 | 115 |
| Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) | $1.1M | 0 | 150 |
| Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children | $499,967 | 0 | 17 |
| A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations | $457,327 | 0 | 7 |
| An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency | $429,247 | 0 | 10 |
| AN OPEN-LABEL, REPEATED-DOSE SAFETY, EFFICACY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF ORAL CTAP101 CAPSULES, IMMEDIATE- RELEASE (IR) CALCIFEDIOL, HIGH-DOSE CHOLECALCIFEROL, AND PARICALCITOL PLUS LOW-DOSE CHOLECALCIFEROL IN PATIENTS WITH SECONDARY HYPERPARATHYROIDISM, STAGE 3 OR 4 CHRONIC KIDNEY DISEASE AND VITAMIN D INSUFFICIENCY | $179,217 | 0 | 17 |
| Safety, Efficacy, PK and PD of CTAP101 (calcifediol) ER Capsules for SHPT in HD Patients VDI | $161,084 | 0 | 21 |
| Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency | $123,491 | 0 | 26 |
| Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency | $70,651 | 0 | 20 |
| SAFETY AND EFFICACY OF RAYALDEE FOR TREATING MILD TO MODERATE COVID-19 | $35,886 | 0 | 2 |
| Safety and dose finding study of different MOD-4023 dose levels compared to daily r-hGH therapy in pre-pubertal growth hormone deficient children | $33,414 | 0 | 6 |
| A MULTI-CENTER STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF CTAP101 EXTENDED-RELEASE CAPSULES TO TREAT SECONDARY HYPERPARATHYROIDISM IN PEDIATRIC SUBJECTS OF AGES 8 TO <18 YEARS WITH STAGE 3 OR 4 CHRONIC KIDNEY DISEASE AND VITAMIN D INSUFFICIENCY. | $26,250 | 0 | 3 |
| CTAP101?CL?2010 | $24,200 | 0 | 5 |
| Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism | $20,205 | 1 | 2 |
| SAFETY AND DOSE FINDING STUDY OF DIFFERENT MOD-4023 DOSE LEVELS COMPARED TO DAILY R-HGH THERAPY IN PRE-PUBERTAL GROWTH HORMONE DEFICIENT CHILDREN | $14,409 | 0 | 1 |
| SAFETY, EFFICACY, PK AND PD OF CTAP101 (CALCIFEDIOL) ER CAPSULES FOR SHPT IN HD PATIENTS VDI | $11,000 | 0 | 6 |
| CTAP101_CL_2010 | $8,950 | 0 | 2 |
| A phase 1/2A, OPEN-LABEL, MULTICENTER, DOSE ESCALATION STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS PROFILE OF A LONG-ACTING RECOMBINANT FACTOR VIIA (MOD-5014) IN ADULT MEN WITH HEMOPHILIA A OR B | $8,029 | 0 | 1 |
| A phase 1/2A, OPEN-LABEL, MULTICARE, DOSE ESCALATION STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS PROFILE OF A LONG-ACTING RECOMBINANT FACTOR VIIA (MOD-5014) IN ADULT MEN WITH HEMOPHILIA A OR B | $3,196 | 0 | 2 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Lawrence Silverman, Md, MD | Pediatric Endocrinology | Morristown, NJ | $228,705 | $0 |
| Dr. Anis Rauf, Do, DO | Critical Care Medicine | Hinsdale, IL | $64,477 | $0 |
| Dr. Judith Ross, Md, MD | Pediatric Endocrinology | Philadelphia, PA | $50,397 | $0 |
| Craig Alter, M.d, M.D | Pediatrics | Philadelphia, PA | $42,400 | $0 |
| Stuart Sprague, Do, DO | Nephrology | Evanston, IL | $39,243 | $0 |
| Dr. Varshasb Broumand, M.d, M.D | Internal Medicine | San Antonio, TX | $38,173 | $0 |
| Robert Rapaport, M.d, M.D | Specialist | New York, NY | $36,725 | $0 |
| Dr. Matt Rosenberg, M.d, M.D | Family Medicine | Jackson, MI | $29,000 | $0 |
| Erdal Sarac, M.d, M.D | Nephrology | Poland, OH | $21,402 | $0 |
| John Heymach, M.d, M.D | Internal Medicine | Houston, TX | $20,000 | $0 |
| Ronald Levy, Md, MD | Internal Medicine | Stanford, CA | $20,000 | $0 |
| Dr. Michael Germain, Md, MD | Nephrology | Springfield, MA | $17,237 | $0 |
| Alexander Swan, Md, MD | Nephrology | Avenel, NJ | $14,925 | $0 |
| Eric Rubin, Md, MD | Diagnostic Radiology | New Orleans, LA | $14,600 | $0 |
| Nelson Kopyt, Do, DO | Nephrology | Allentown, PA | $13,354 | $0 |
| Arnold Silva, Md, Phd, MD, PHD | Internal Medicine | Meridian, ID | $11,525 | $0 |
| Unknown Provider | — | — | $11,427 | $0 |
| Dr. Harry Dounis, Do, DO | Nephrology | Neptune, NJ | $11,285 | $0 |
| Dr. Leonard Stern, M.d, M.D | Nephrology | New York, NY | $8,897 | $0 |
| Dr. Christopher Kwoh, M.d, M.D | Nephrology | Houston, TX | $7,922 | $0 |
| Dr. Geoffrey Block, Md, MD | Nephrology | Lone Tree, CO | $6,671 | $0 |
| Jay Wish, Md, MD | Nephrology | Indianapolis, IN | $6,145 | $0 |
| William Kendrick, M.d, M.D | Nephrology | Greenville, NC | $6,030 | $0 |
| Dr. Donald Molony, M.d, M.D | Internal Medicine | Houston, TX | $5,846 | $0 |
| Dr. Spiros Arbes, Md, MD | Nephrology | Eatontown, NJ | $5,714 | $0 |
Ad
Top Products
- RAYALDEE $6.0M
- Rayaldee $3.9M
Associated Products (8)
- RAYALDEE $6.0M
- Rayaldee $3.9M
- Benign Prostatic Hyperplasia $1.1M
- CTAP101 $548,822
- Growth Hormone Deficiency $457,327
- MOD-4023 $298,245
- none $123,326
- Rayaldee (old) $11,578
Payment Categories
- Food & Beverage $746,401
- Consulting $403,864
- Travel & Lodging $12,316
- Research $12.4M
About OPKO Pharmaceuticals, LLC
OPKO Pharmaceuticals, LLC has made $14.2M in payments to 6,949 healthcare providers, recorded across 55,304 transactions in the CMS Open Payments database. In 2024, the company paid $740,737. The top product by payment volume is RAYALDEE ($6.0M).
Payments were distributed across 118 medical specialties. The top specialty by payment amount is Nephrology ($799,531 to 3,194 doctors).
Payment categories include: Food & Beverage ($746,401), Consulting ($403,864), Research ($12.4M), Travel & Lodging ($12,316).
OPKO Pharmaceuticals, LLC is associated with 8 products in the CMS Open Payments database, including RAYALDEE, Rayaldee, and Benign Prostatic Hyperplasia.